Michael Davidson

Revitas, Inc. engages in the delivering integrated solutions for contract, revenue and compliance management. The company was founded in 1989 and is headquartered in Philadelphia, PA.

ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA.

Diasome Pharmaceuticals, Inc. operates as a clinical stage diabetes therapeutics company which designs and develops insulin-based therapies for the treatment of diabetes. It focuses on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The company’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. The firm’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells. The company was founded by Len Rosenberg, Lance Converse, W. Blair Geho and Robert Geho in 2004 and is headquartered in Cleveland, OH.

Sequenta, Inc. operates as a biotech company which discovers and develops clinical diagnostics based on immune system status. It develops molecular diagnostic assays based on a sequencing approach to the profiling of T and B cell receptor repertoires. The firm also provides sequencing-based test for minimal residual disease for leukemia and lymphoma. The company was founded by Thomas D. Willis and Malek Faham in 2007 and is headquartered in South San Francisco, CA.

Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland.

Ernst & Young provides accounting services. Its services include auditing, accounting, tax and transaction services, assurance and advisory business, online transaction advisory and a wide range of financial services. The company was founded by Arthur Young and Alwin C. Ernst in 1881 and is headquartered in Kansas City, MO.

Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France.

Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom.

LinguaFlex, Inc. develops, manufactures and distributes medical devices for the treatment of sleep apnea. It offers the LinguaFlex Tongue Retractor which is a minimally invasive device designed to be inserted into the tongue by a thin needle. The LinguaFlex Tongue Retractor is designed not to interfere with normal tongue functions such as speech and swallowing and to be removed or replaced in a doctor’s office in a short period of time without the need for anesthesia. The company was founded by Ira Sanders in 2007 and is headquartered in Pittsburgh, PA.

Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium.

ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands.

SEPS Pharma NV provides controlled drug delivery and develops self emulsifying pro drug systems. Its services include preformulation, formulation development and analytical development. The company was founded on October 19, 2007 and is headquartered in Diepenbeek, Belgium.

Mind-NRG SARL specializes in research and development programs with focus on the treatment psychiatric and neurologic diseases. The company was founded in 2010 and is headquartered in Geneva, Switzerland.

Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom.

Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands.

Kymo Therapeutics Ltd. develops and commercializes therapeutic products . The company was founded on May 23, 2016 and is headquartered in Hatfield, the United Kingdom.

Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA.

Mavalon Therapeutics Ltd. develops orally available small molecule able to induce glial cell line-derived neurotropic factor production within the brain of parkinson’s patients. The company is headquartered in Hatfield, the United Kingdom.

Kaerus Bioscience France SASU engages in research and development in biotechnology. The company was founded on February 23, 2017 and is headquartered in Orléans, France.

Human Antibody Factory Ltd. provides research and experimental development on biotechnology. The company was founded by David John Grainger and is headquartered in Hatfield, the United Kingdom.

Inexia Ltd. develops intranasal orexin positive modulators for the treatment of narcolepsy. The company is headquartered in London, the United Kingdom.

Orexia Ltd. develop orally administered orexin positive modulators for the treatment of neurological diseases. The company was founded on October 5, 2018 and is headquartered in London, the United Kingdom.

Villaris Therapeutics, Inc. is an asset-centric biopharmaceutical company. The company is based in Cary, NC. The company was founded in 2019 by John Harris. The CEO is Andrea Epperly.